The human microbiome is the community of bacteria and microorganisms that lives in association with the human body.
A Human-First Discovery approach accelerates our development of microbial therapeutics.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutic platform company, announced today that Zain Kassam, MD, MPH, has been appointed Chief Medical Officer (CMO) effective September 1, 2019. Dr. Kassam will lead the advancement of Finch’s microbiome therapeutics for recurrent C. difficile infection, ulcerative colitis, and autism spectrum disorder through the clinical development and regulatory submission process.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today the completion of a $53 million Series C financing. The financing comes from new investors including OCV Partners, Susquehanna International Group (SIG), Symbiosis LLC and the Trans-Pacific Technology Fund, as well as existing investors, including Avenir Growth Capital, Morgan Noble, Shumway Capital, and Willett Advisors.
On June 13, FDA reported that an immunocompromised patient treated with FMT died from a drug resistant infection. Importantly, this patient was not treated by Finch or our collaborator, OpenBiome. The FDA has communicated new mandatory screening standards, which Finch already exceeds. As a result, there is no impact on Finch’s work and our PRISM 3 and PRISM-EXT studies continue uninterrupted.
The infection occurred in a high-risk patient that received material from a donor that was not screened for a common drug resistant pathogen, resulting in exposure and subsequent infection. Finch has a thorough screening program which incorporates a panel of 30+ laboratory tests, including the agent associated with this adverse event, as part of our commitment to patient safety.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its Full-Spectrum Microbiota® (FSM®) therapy for the treatment of children with Autism Spectrum Disorder (ASD). Fast Track designation is intended to facilitate development and expedite review of therapies designed to treat serious conditions and fill an unmet medical need.
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to investigational drug CP101 for the treatment of patients with recurrent Clostridium difficile (C. difficile) infection.
“Smith, who has a PhD in microbiology, has devoted much of his adult life to treating and curing C. diff, partly by founding two companies—OpenBiome and Finch Laboratories. The former is basically a non-profit “stool bank” that collects life-giving samples from donors, and the latter is a research and development company working on making the treatment available to all who need it—including in pill form.”
When Smith launched OpenBiome, the entire landscape of CDI treatment changed. Now that he is at Finch Therapeutics, Smith is ready to change the treatment landscapes of many more diseases. “If we could manage this ecosystem and intentionally modulate the composition of this community,” he declares, “we could radically impact the drivers of morbidity and mortality.”
‘Meanwhile, the success of the study in Arizona has prompted America’s Food and Drug Administration (FDA) to look into the matter. A firm called Finch Therapeutics Group, based in Massachusetts, hopes to commercialise the use of MTT as a treatment for autism and the FDA has now granted this effort “fast track” status, which should speed up the review process.’